The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis
Open accessAbstract
The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in industrialized nations, poses a great threat to human health and defines a need to develop new, effective and inexpensive anti-tubercular agents. Previously we developed a chemical systems biology approach to identify off-targets of major pharmaceuticals on a proteome-wide scale. In this paper we further demonstrate the value of this approach through the discovery that existing commercially available drugs, prescribed for the treatment of Parkinson's disease, have the potential to treat MDR and XDR tuberculosis. These drugs, entacapone and tolcapone, are predicted to bind to the enzyme InhA and directly inhibit substrate binding. The prediction is validated by in vitro and InhA kinetic assays using tablets of Comtan, whose active component is entacapone. The minimal inhibition concentration (MIC(99)) of entacapone for Mycobacterium tuberculosis (M.tuberculosis) is approximately 260.0 microM, well below the toxicity concentration determined by an in vitro cytotoxicity model using a human neuroblastoma cell line. Moreover, kinetic assays indicate that Comtan inhibits InhA activity by 47.0% at an entacapone concentration of approximately 80 microM. Thus the active component in Comtan represents a promising lead compound for developing a new class of anti-tubercular therapeutics with excellent safety profiles. More generally, the protocol described in this paper can be included in a drug discovery pipeline in an effort to discover novel drug leads with desired safety profiles, and therefore accelerate the development of new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Encyclopedia of Pharmaceutical Technology
Swarbrick, J. (2013) · CRC Press eBooks · doi:10.1201/b19309 · Cited by 1,794
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis
Takayama, K., Wang, C., & Besra, G. S. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.81-101.2005 · Cited by 660
Jain, A. N. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9114-2 · Cited by 587
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C. T., Scozzafava, A., & Klebe, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030912m · Cited by 454
Deshpande, N. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki057 · Cited by 340
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Self-citationAn improved relaxed complex scheme for receptor flexibility in computer-aided drug design
Amaro, R. E., Baron, R., & McCammon, J. A. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9159-2 · Cited by 321
Mechanism of thioamide drug action against tuberculosis and leprosy
Wang, F., Langley, R., Gulten, G., Dover, L. G., Besra, G. S., Jacobs, W. R., & Sacchettini, J. C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062100 · Cited by 303
Rozwarski, D. A., Vilchèze, C., Sugantino, M., Bittman, R., & Sacchettini, J. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15582 · Cited by 290
Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase
Kuo, M. R., Morbidoni, H. R., Alland, D., Sneddon, S. F., Gourlie, B. B., Staveski, M. M., Leonard, M., Gregory, J. S., Janjigian, A. D., Yee, C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211968200 · Cited by 263
He, X., Alian, A., Stroud, R., & Ortiz de Montellano, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060715y · Cited by 257
Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening
Xia, M., Huang, R., Witt, K. L., Southall, N., Fostel, J., Cho, M.-H., Jadhav, A., Smith, C. S., Inglese, J., Portier, C. J., et al. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.10727 · Cited by 255
Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Self-citationeHiTS: A new fast, exhaustive flexible ligand docking system
Zsoldos, Z., Reid, D., Simon, A., Sadjad, S. B., & Johnson, A. P. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2006.06.002 · Cited by 249
Xie, L., Li, J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000387 · Cited by 247
Self-citationXie, L., & Bourne, P. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704422105 · Cited by 245
Self-citationSullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratton, C. F., Li, H.-J., Kaur, T., Amin, A., Johnson, F., et al. (2006) · ACS Chemical Biology · doi:10.1021/cb0500042 · Cited by 236
Self-citationFinding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Selective Optimization of Side Activities: Another Way for Drug Discovery
Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 201
From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis
Dorman, S. E., & Chaisson, R. E. (2007) · Nature Medicine · doi:10.1038/nm0307-295 · Cited by 189
Buchmeier, N. A., Newton, G. L., Koledin, T., & Fahey, R. C. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03416.x · Cited by 180
Self-citationIndole Naphthyridinones as Inhibitors of Bacterial Enoyl-ACP Reductases FabI and FabK
Seefeld, M. A., Miller, W. H., Newlander, K. A., Burgess, W. J., DeWolf, W. E., Elkins, P. A., Head, M. S., Jakas, D. R., Janson, C. A., Keller, P. M., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204035 · Cited by 163
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides
He, X., Alian, A., & de Montellano, P. R. O. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.013 · Cited by 158
Betts, J. C., McLaren, A. S., Lennon, M. G., Kelly, F. M., Lukey, P. T., Blakemore, S. J., & Duncan, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2903-2913.2003 · Cited by 145
Selective optimization of side activities: the SOSA approach
Wermuth, C. G. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03686-x · Cited by 144
Xie, L., & Bourne, P. E. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s4-s9 · Cited by 138
Self-citationDiscovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei
Amaro, R. E., Schnaufer, A. C., Interthal, H., Hol, W. G. J., Stuart, K. D., & McCammon, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805820105 · Cited by 127
Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FabI)
Miller, W. H., Seefeld, M. A., Newlander, K. A., Uzinskas, I. N., Burgess, W. J., Heerding, D. A., Yuan, C. C.-K., Head, M. S., Payne, D. J., Rittenhouse, S. F., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020050+ · Cited by 113
Xie, L., Xie, L., & Bourne, P. E. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp220 · Cited by 93
Self-citationXie, L., Wang, J., & Bourne, P. E. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030217 · Cited by 89
Self-citationKorlipara, P., Cooper, J. A. D., & Schapira, A. H. V. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.015 · Cited by 53
Tolcapone-Related Liver Dysfunction
Borges, N. (2003) · Drug Safety · doi:10.2165/00002018-200326110-00001 · Cited by 46
Tervo, A. J., Nyrönen, T., Rönkkö, T., & Poso, A. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/b:jcam.0000021831.47952.a7 · Cited by 34
Cited by
Molecular Docking: Shifting Paradigms in Drug Discovery
Pinzi, L., & Rastelli, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184331 · Cited by 2,344
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Metadata
- Authors
- Kinnings, S. L., Liu, N., Buchmeier, N., Tonge, P. J., Xie, L., & Bourne, P. E.
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-03
- Volume
- 5
- Issue
- 7
- Pages
- e1000423
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2076764146
- Cited by
- 319
- References
- 44
- FWCI
- 29.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.